RxDoctor Payments Data

Amanda Crowe, MD

Anatomic Pathology & Clinical Pathology · Homewood, ALNPI 1073723383

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.9% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AstraZeneca at 24.8% of the total. Reporting peaked in 2024 at $348 and has fallen 59.0% since, to $143 in 2025. Among anatomic pathology & clinical pathology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$832in general payments, 2019–2025

Across 41 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$206
  • Merck$161
  • Procept Biorobotics Corporation$88
  • Dendreon Pharmaceuticals LLC$66
  • Novartis$51
  • Roche Diagnostics Corporation$47
  • plus $211 from 8 others

What the payments were for

  • Food & beverage$81498%
  • Education$182%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$832 in reported general payments places this provider in the 90th percentile of 115 anatomic pathology & clinical pathology providers in Alabama.

See all anatomic pathology & clinical pathology providers in Alabama

Medicare billing

Part B allowed, 2024
$124,357
Medicare patients
364
Services billed
568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other anatomic pathology & clinical pathology in Homewood

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →